Natesto Effects on Reproductive Hormones and Semen Parameters: Results from an Ongoing Single-center, Investigator-initiated Phase IV Clinical Trial
Thomas Masterson *, Manuel Molina, Emad Ibrahim, Ranjith Ramasamy
Department of Urology, University of Miami, Miami, FL, USA
"We launched our clinical trial to evaluate the role of Natesto on semen parameters and reproductive hormones in November 2017 with the intent of enrolling 40 participants (Mobile and Remote Monitoring of Seating Pressure for Wheelchair Users With SCI - Full Text View - ClinicalTrials.gov NCT03203681). It is an ongoing, single-institution, prospective investigator-initiated study funded by Aytu Biosciences. Men eligible for the study are aged 18–55 yr, with at least two T levels <350 ng/dl (drawn before 10 AM) and have two semen analyses (SA) with total motile sperm count (TMSC) >5 million. All men are naïve to T therapy prior to enrolment"
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.